AFMD

Affimed N.V. (AFMD) | Rumor.io

Affimed

AFMD

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)71%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about AFMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 20

Affimed N.V. (AFMD) has been delisted from NASDAQ and is now trading on the OTC under the ticker "AFMDQ".
The company's stock price has been volatile, with some users suggesting it may move to the expert market due to outdated financials.
Trading volume has been high, with over 1 million shares traded, and some users are speculating about the company's earnings.

Generated by AI

Sentiment

Of the messages about AFMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	57.14% +1.94
Bearish	—	—	0%	42.86% -1.94

Bullish· May 19

Affimed N.V. ($AFMD) has a history of significant price increases after receiving a delisting notice, potentially leading to a spike in its stock price.
The company has a strong cash position, with $20M in cash reserves, making it an attractive investment opportunity in the eyes of some analysts.
Despite some selling pressure, buying is currently outweighing selling, and the spread has tightened, indicating a potential upward trend in the stock's price.

Bearish· May 16

$AFMD's trend reversal has been confirmed, indicating a potential decline in the stock's value.
The company is facing a delisting risk, with some predicting it will be delisted next week, potentially leading to a significant drop in the stock's price.
$AFMD's price surge is attributed to a short squeeze, but many believe the stock will eventually collapse, with some predicting a return to $0.60 or even $0.

Generated by AI

Topics

Of the messages about AFMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	0%
Macro	—	—	0%	0%
Earnings	—	—	0%	0%
Controversies	—	—	0%	0%
Announcements	—	—	100%	100%
Analysts	—	—	0%	0%

Earnings· Nov 7

Affimed N.V. ($AFMD) reported Q3 EPS loss of €0.18 and revenue of €0.47M, down 50% Y/Y.
The company's Q3 earnings beat estimates, with a reported EPS of $0.18.
Affimed N.V. released its earnings results, with revenue of $0.50M, beating estimates by $0.03 EPS.

Analysts· Dec 12

H.C. Wainwright initiated coverage of Affimed (AFMD) with a Buy rating and $6 price target, citing the potential of AFM13 and AFM24 to unleash the therapeutic potential of innate immune cells.
Wells Fargo and Piper Sandler maintained Overweight ratings on AFMD, with Wells Fargo lowering its price target to $7 and Piper Sandler lowering its price target to $6.
SVB Leerink lowered its price target on AFMD to $6, while Truist lowered its price target to $8, citing various analyst reports and research notes.

Announcements· Dec 5

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Affimed's combination therapy involving Acimtamig and AlloNK for the treatment of relapsed or refractory Hodgkin Lymphoma.
The RMAT designation is based on early efficacy data demonstrating an 83.3% overall response rate and a 50% complete response rate.
The RMAT designation could potentially lead to accelerated approval of Affimed's combination therapy, which could have a significant impact on the company's stock price.

Technical Analysis· May 16

$AFMD has shown a trend reversal and possibly a cup and handle formation, with support at $0.29 and a potential breakout above $0.40.
The stock has displayed strong volume and a clean bounce off $0.23, with breakout levels at $0.40, $0.45, and $0.52, and stretch targets at $0.65 and $0.72.
The stock is forming a bullish cup and handle pattern, and a push above the $0.43/$0.46 zone could signal another run, with some analysts watching for a reversal and others expecting a continued breakout.

Generated by AI

Community

Of the messages about AFMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	86.58%
Newcomers	—	—	0%	13.42%

Regulars· May 14

Management quality is crucial for biotech investing, as seen in Affimed's struggles under its current leadership.
The company's German location and specific managers, including Adi Hoess and Denise Mueller, are red flags for investors.
Affimed's recent delisting from the Nasdaq is a significant concern, highlighting the company's financial struggles and potential for further losses.

Newcomers· May 16

Delisting on Tuesday has some market participants looking to buy $AFMD before more dilution, while others are looking to exit.
$AFMD's high volume and share count of 15 million may be attracting some investors.
Some market participants are considering $AFMD for its potential as a penny stock.

Generated by AI

Also Discussed

Investors talking about AFMD also mention

#	Name	Attention
1	Palvella Therapeutics IncPIRS	0%0
2	Fate Therapeutics Inc.FATE	0%new
3	ONCT - Oncternal Therapeutics, Inc.	——
4	Calithera Biosciences Inc.CALA	0%0
5	ProQR Therapeutics N.V. Ordinary SharesPRQR	0%0
6	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
7	BLCM - Bellicum Pharmaceuticals, Inc.	——
8	ALX Oncology Holdings Inc.ALXO	0%0
9	Immatics N.V.IMTX	0%0
10	Mereo BioPharma Group plc ADRMREO	0.01%-0.01

Affimed N.V.

Location

Social

What share of all stock conversation is about AFMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 20

Affimed N.V. (AFMD) has been delisted from NASDAQ and is now trading on the OTC under the ticker "AFMDQ".
The company's stock price has been volatile, with some users suggesting it may move to the expert market due to outdated financials.
Trading volume has been high, with over 1 million shares traded, and some users are speculating about the company's earnings.

Generated by AI

Sentiment

Of the messages about AFMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	57.14% +1.94
Bearish	—	—	0%	42.86% -1.94

Bullish· May 19

Affimed N.V. ($AFMD) has a history of significant price increases after receiving a delisting notice, potentially leading to a spike in its stock price.
The company has a strong cash position, with $20M in cash reserves, making it an attractive investment opportunity in the eyes of some analysts.
Despite some selling pressure, buying is currently outweighing selling, and the spread has tightened, indicating a potential upward trend in the stock's price.

Bearish· May 16

$AFMD's trend reversal has been confirmed, indicating a potential decline in the stock's value.
The company is facing a delisting risk, with some predicting it will be delisted next week, potentially leading to a significant drop in the stock's price.
$AFMD's price surge is attributed to a short squeeze, but many believe the stock will eventually collapse, with some predicting a return to $0.60 or even $0.

Generated by AI

Topics

Of the messages about AFMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	0%
Macro	—	—	0%	0%
Earnings	—	—	0%	0%
Controversies	—	—	0%	0%
Announcements	—	—	100%	100%
Analysts	—	—	0%	0%

Earnings· Nov 7

Affimed N.V. ($AFMD) reported Q3 EPS loss of €0.18 and revenue of €0.47M, down 50% Y/Y.
The company's Q3 earnings beat estimates, with a reported EPS of $0.18.
Affimed N.V. released its earnings results, with revenue of $0.50M, beating estimates by $0.03 EPS.

Analysts· Dec 12

H.C. Wainwright initiated coverage of Affimed (AFMD) with a Buy rating and $6 price target, citing the potential of AFM13 and AFM24 to unleash the therapeutic potential of innate immune cells.
Wells Fargo and Piper Sandler maintained Overweight ratings on AFMD, with Wells Fargo lowering its price target to $7 and Piper Sandler lowering its price target to $6.
SVB Leerink lowered its price target on AFMD to $6, while Truist lowered its price target to $8, citing various analyst reports and research notes.

Announcements· Dec 5

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Affimed's combination therapy involving Acimtamig and AlloNK for the treatment of relapsed or refractory Hodgkin Lymphoma.
The RMAT designation is based on early efficacy data demonstrating an 83.3% overall response rate and a 50% complete response rate.
The RMAT designation could potentially lead to accelerated approval of Affimed's combination therapy, which could have a significant impact on the company's stock price.

Technical Analysis· May 16

$AFMD has shown a trend reversal and possibly a cup and handle formation, with support at $0.29 and a potential breakout above $0.40.
The stock has displayed strong volume and a clean bounce off $0.23, with breakout levels at $0.40, $0.45, and $0.52, and stretch targets at $0.65 and $0.72.
The stock is forming a bullish cup and handle pattern, and a push above the $0.43/$0.46 zone could signal another run, with some analysts watching for a reversal and others expecting a continued breakout.

Generated by AI

Community

Of the messages about AFMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	86.58%
Newcomers	—	—	0%	13.42%

Regulars· May 14

Management quality is crucial for biotech investing, as seen in Affimed's struggles under its current leadership.
The company's German location and specific managers, including Adi Hoess and Denise Mueller, are red flags for investors.
Affimed's recent delisting from the Nasdaq is a significant concern, highlighting the company's financial struggles and potential for further losses.

Newcomers· May 16

Delisting on Tuesday has some market participants looking to buy $AFMD before more dilution, while others are looking to exit.
$AFMD's high volume and share count of 15 million may be attracting some investors.
Some market participants are considering $AFMD for its potential as a penny stock.

Generated by AI

Affimed

Social

May 20

Sentiment

Bullish· May 19

Bearish· May 16

Topics

Earnings· Nov 7

Analysts· Dec 12

Announcements· Dec 5

Technical Analysis· May 16

Community

Regulars· May 14

Newcomers· May 16

Also Discussed

Affimed N.V.

Company Information

Location

Social

May 20

Sentiment

Bullish· May 19

Bearish· May 16

Topics

Earnings· Nov 7

Analysts· Dec 12

Announcements· Dec 5

Technical Analysis· May 16

Community

Regulars· May 14

Newcomers· May 16

Also Discussed